Navigation Links
Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine?
Date:8/24/2009

ST. LOUIS, Aug. 24 /PRNewswire/ -- Recent developments toward addressing the harmful health effects of the herbicide Atrazine have attorney and clean water advocate Steve Tillery cautiously optimistic that the country is moving closer toward transparency and accountability for the herbicide's manufacturers.

"Just within the past 48 hours, articles appearing in the New York Times and the Peoria Journal Star have underscored the serious need to closely examine and address the negative impact the herbicide Atrazine is having on our environment and the health of our citizens," said Tillery.

"The public assumes that a governmental entity like the U.S. Environmental Protection Agency (U.S. EPA), is acting to protect them and keep them safe. When it comes to Atrazine, the EPA has earned a failing grade," Tillery says. "Current initiatives are a step in the right direction, but much more needs to be done," Tillery added.

Tillery is referring to an announcement made earlier this Spring by the U.S. EPA to screen 67 pesticides, including Atrazine - the most commonly used herbicide in the United States, for their potential to damage human reproduction and growth. The announcement moved forward the Endocrine Disruptor Screening Program, which is currently proceeding on 3 fronts: 1) performing scientific and technical testing needed to validate the endocrine disruptor screens and tests; 2) setting priorities for selecting chemicals for initial screening and testing; and 3) developing the policies and procedures the Agency will use to require testing. By U.S. EPA's working definition, endocrine disruptors "interfere with synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body that are responsible for the maintenance of homeostasis (normal cell metabolism), reproduction, development and/or behavior." Tillery points to countless studies which have demonstrated that Atrazine is a potent endocrine disruptor (Albanito, et. Al Environmental Health Perspectives 2008 116 (12): 1648-53.) and notes that "all vertebrates (fish, amphibians, reptiles, birds and mammals, including humans) are fundamentally similar during early embryonic development. Scientists can therefore use the evidence acquired on other species to make predictions about endocrine disrupting effects on humans." Numerous studies conducted to date have raised serious concerns about the link to health effects when people are exposed to Atrazine, such as congestion of the heart, lungs and kidneys; low blood pressure; muscle spasms; weight loss; damage to adrenal glands; cardio-vascular damage; retinal and muscle degeneration; cancer and other adverse developmental and reproductive conditions.

Responding to news releases by Syngenta citing studies favorable to Atrazine, Tillery has one response: "Whenever you see any study favorable to this chemical, ask whether the scientists performing the study were on Syngenta's payroll, directly or indirectly."

Tillery says that according to a lawsuit filed by the Natural Resources Defense Council, there were numerous secret meetings held between Syngenta, the largest manufacturer of Atrazine (based in Switzerland), and the EPA during the critical Atrazine re-registration - a process that resulted in the continuation of the unrestrained use of Atrazine in the U.S. (the use of Atrazine was banned by the European Union in 2004). "Whether or not the average person agrees with his/her government, all Americans should be able to rely on the basic integrity of the federal agency charged with keeping our drinking water safe," said Tillery.

Tillery also said he's glad to see that Congress is taking further steps with the recent re-introduction of the Clean Water Restoration Act, to restore protections for waterways throughout the country that impact the drinking water of more than 100 million Americans. "We're hopeful that Congress and the Administration will continue to move forward to ensure safe and uncontaminated drinking water for all Americans," Tillery added.

"The clock is ticking and I believe that time is running out for the manufacturers of Atrazine. Until now there has been zero accountability for the very companies which have profited enormously while polluting our drinking water. They should clean up their own mess, not rely on the American public to do it for them." says Tillery. Tillery's law firm, Korein Tillery, filed a class action lawsuit in August of 2004 on behalf of Holiday Shores Sanitary District, located in Madison County, Illinois and all other Illinois water districts which had suffered Atrazine contamination of their water sources(s) at any measurable level. The lawsuit seeks damages for the ongoing costs of filtering Atrazine as well as for proper filtration systems that will protect the public from the dangers of Atrazine. "I will not rest until manufacturers like Syngenta are held accountable to clean up the mess they are creating in our water systems and until every American is assured safe and uncontaminated drinking water," Tillery said.


'/>"/>
SOURCE Korein Tillery
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Korein Tillery Takes Herbicide Atrazine Case to the Court of Public Opinion
2. Running shipwreck simulations backwards helps identify dangerous waves
3. Pricey Running Shoes Not Worth It: Study
4. Kids Respiratory Virus Season Off and Running
5. Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles
6. OrthoLite Joins the Teva U.S. Mountain Running Team
7. Ex-Cowboys Running Back Ron Springs Named Plaintiff in Constitutional Challenge to Texas Malpractice Award Cap
8. Running Pioneer Kathrine Switzer Will Headline Women on the Move Conference August 13-15, 2008 in Spearfish, SD
9. 55-Year-Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7.com
10. Wounded Marines Running Their Way to Recovery at Fourth Annual Pats Run
11. Verathon Inc., Recognized, Second Year Running, as Outstanding Workplace in Washington State by Washington CEO Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today reported its fourth quarter and full year ... vivo therapeutic genome editing," said Edward Lanphier, ... finger nuclease (ZFN) technology leads the therapeutic genome ... competencies necessary to move our ground-breaking genome editing ...
Breaking Medicine Technology: